Efficacy, Safety, and Tolerability of Atogepant for the Prevention of Chronic Migraine

NCT03855137 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

778

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Migraine

Interventions

DRUG: Atogepant 30 mg
DRUG: Atogepant 60 mg
DRUG: Placebo

Sponsor

Allergan